243 related articles for article (PubMed ID: 30880120)
1. Identification of a neoantigen epitope in a melanoma patient with good response to anti-PD-1 antibody therapy.
Nonomura C; Otsuka M; Kondou R; Iizuka A; Miyata H; Ashizawa T; Sakura N; Yoshikawa S; Kiyohara Y; Ohshima K; Urakami K; Nagashima T; Ohnami S; Kusuhara M; Mitsuya K; Hayashi N; Nakasu Y; Mochizuki T; Yamaguchi K; Akiyama Y
Immunol Lett; 2019 Apr; 208():52-59. PubMed ID: 30880120
[TBL] [Abstract][Full Text] [Related]
2. HLA class I loss in metachronous metastases prevents continuous T cell recognition of mutated neoantigens in a human melanoma model.
Schrörs B; Lübcke S; Lennerz V; Fatho M; Bicker A; Wölfel C; Derigs P; Hankeln T; Schadendorf D; Paschen A; Wölfel T
Oncotarget; 2017 Apr; 8(17):28312-28327. PubMed ID: 28423700
[TBL] [Abstract][Full Text] [Related]
3. Immunological ignorance is an enabling feature of the oligo-clonal T cell response to melanoma neoantigens.
Linette GP; Becker-Hapak M; Skidmore ZL; Baroja ML; Xu C; Hundal J; Spencer DH; Fu W; Cummins C; Robnett M; Kaabinejadian S; Hildebrand WH; Magrini V; Demeter R; Krupnick AS; Griffith OL; Griffith M; Mardis ER; Carreno BM
Proc Natl Acad Sci U S A; 2019 Nov; 116(47):23662-23670. PubMed ID: 31685621
[TBL] [Abstract][Full Text] [Related]
4. Isolation of neoantigen-specific T cells from tumor and peripheral lymphocytes.
Cohen CJ; Gartner JJ; Horovitz-Fried M; Shamalov K; Trebska-McGowan K; Bliskovsky VV; Parkhurst MR; Ankri C; Prickett TD; Crystal JS; Li YF; El-Gamil M; Rosenberg SA; Robbins PF
J Clin Invest; 2015 Oct; 125(10):3981-91. PubMed ID: 26389673
[TBL] [Abstract][Full Text] [Related]
5. Late-differentiated effector neoantigen-specific CD8+ T cells are enriched in peripheral blood of non-small cell lung carcinoma patients responding to atezolizumab treatment.
Fehlings M; Jhunjhunwala S; Kowanetz M; O'Gorman WE; Hegde PS; Sumatoh H; Lee BH; Nardin A; Becht E; Flynn S; Ballinger M; Newell EW; Yadav M
J Immunother Cancer; 2019 Sep; 7(1):249. PubMed ID: 31511069
[TBL] [Abstract][Full Text] [Related]
6. An immunogenic personal neoantigen vaccine for patients with melanoma.
Ott PA; Hu Z; Keskin DB; Shukla SA; Sun J; Bozym DJ; Zhang W; Luoma A; Giobbie-Hurder A; Peter L; Chen C; Olive O; Carter TA; Li S; Lieb DJ; Eisenhaure T; Gjini E; Stevens J; Lane WJ; Javeri I; Nellaiappan K; Salazar AM; Daley H; Seaman M; Buchbinder EI; Yoon CH; Harden M; Lennon N; Gabriel S; Rodig SJ; Barouch DH; Aster JC; Getz G; Wucherpfennig K; Neuberg D; Ritz J; Lander ES; Fritsch EF; Hacohen N; Wu CJ
Nature; 2017 Jul; 547(7662):217-221. PubMed ID: 28678778
[TBL] [Abstract][Full Text] [Related]
7. Prospective identification of neoantigen-specific lymphocytes in the peripheral blood of melanoma patients.
Gros A; Parkhurst MR; Tran E; Pasetto A; Robbins PF; Ilyas S; Prickett TD; Gartner JJ; Crystal JS; Roberts IM; Trebska-McGowan K; Wunderlich JR; Yang JC; Rosenberg SA
Nat Med; 2016 Apr; 22(4):433-8. PubMed ID: 26901407
[TBL] [Abstract][Full Text] [Related]
8. Neoantigen-reactive T cells exhibit effective anti-tumor activity against colorectal cancer.
Yu Y; Zhang J; Ni L; Zhu Y; Yu H; Teng Y; Lin L; Xue Z; Xue X; Shen X; Song H; Su X; Sun W; Cai Z
Hum Vaccin Immunother; 2022 Dec; 18(1):1-11. PubMed ID: 33689574
[TBL] [Abstract][Full Text] [Related]
9. pTuneos: prioritizing tumor neoantigens from next-generation sequencing data.
Zhou C; Wei Z; Zhang Z; Zhang B; Zhu C; Chen K; Chuai G; Qu S; Xie L; Gao Y; Liu Q
Genome Med; 2019 Oct; 11(1):67. PubMed ID: 31666118
[TBL] [Abstract][Full Text] [Related]
10. Induction of Neoantigen-Specific Cytotoxic T Cells and Construction of T-cell Receptor-Engineered T Cells for Ovarian Cancer.
Matsuda T; Leisegang M; Park JH; Ren L; Kato T; Ikeda Y; Harada M; Kiyotani K; Lengyel E; Fleming GF; Nakamura Y
Clin Cancer Res; 2018 Nov; 24(21):5357-5367. PubMed ID: 29720506
[No Abstract] [Full Text] [Related]
11. T-cell Responses to
Deniger DC; Pasetto A; Robbins PF; Gartner JJ; Prickett TD; Paria BC; Malekzadeh P; Jia L; Yossef R; Langhan MM; Wunderlich JR; Danforth DN; Somerville RPT; Rosenberg SA
Clin Cancer Res; 2018 Nov; 24(22):5562-5573. PubMed ID: 29853601
[No Abstract] [Full Text] [Related]
12. A ras-mutated peptide targeted by CTL infiltrating a human melanoma lesion.
Linard B; Bézieau S; Benlalam H; Labarrière N; Guilloux Y; Diez E; Jotereau F
J Immunol; 2002 May; 168(9):4802-8. PubMed ID: 11971032
[TBL] [Abstract][Full Text] [Related]
13. Measuring Tumor Mutational Burden Using Whole-Exome Sequencing.
Vilimas T
Methods Mol Biol; 2020; 2055():63-91. PubMed ID: 31502147
[TBL] [Abstract][Full Text] [Related]
14. Neoantigen-specific immunity in low mutation burden colorectal cancers of the consensus molecular subtype 4.
van den Bulk J; Verdegaal EME; Ruano D; Ijsselsteijn ME; Visser M; van der Breggen R; Duhen T; van der Ploeg M; de Vries NL; Oosting J; Peeters KCMJ; Weinberg AD; Farina-Sarasqueta A; van der Burg SH; de Miranda NFCC
Genome Med; 2019 Dec; 11(1):87. PubMed ID: 31888734
[TBL] [Abstract][Full Text] [Related]
15. The intronic region of an incompletely spliced gp100 gene transcript encodes an epitope recognized by melanoma-reactive tumor-infiltrating lymphocytes.
Robbins PF; El-Gamil M; Li YF; Fitzgerald EB; Kawakami Y; Rosenberg SA
J Immunol; 1997 Jul; 159(1):303-8. PubMed ID: 9200467
[TBL] [Abstract][Full Text] [Related]
16. Isolation of T-Cell Receptors Specifically Reactive with Mutated Tumor-Associated Antigens from Tumor-Infiltrating Lymphocytes Based on CD137 Expression.
Parkhurst M; Gros A; Pasetto A; Prickett T; Crystal JS; Robbins P; Rosenberg SA
Clin Cancer Res; 2017 May; 23(10):2491-2505. PubMed ID: 27827318
[No Abstract] [Full Text] [Related]
17. Identification of a tyrosinase epitope recognized by HLA-A24-restricted, tumor-infiltrating lymphocytes.
Kang X; Kawakami Y; el-Gamil M; Wang R; Sakaguchi K; Yannelli JR; Appella E; Rosenberg SA; Robbins PF
J Immunol; 1995 Aug; 155(3):1343-8. PubMed ID: 7543520
[TBL] [Abstract][Full Text] [Related]
18. Neoantigen identification strategies enable personalized immunotherapy in refractory solid tumors.
Chen F; Zou Z; Du J; Su S; Shao J; Meng F; Yang J; Xu Q; Ding N; Yang Y; Liu Q; Wang Q; Sun Z; Zhou S; Du S; Wei J; Liu B
J Clin Invest; 2019 May; 129(5):2056-2070. PubMed ID: 30835255
[TBL] [Abstract][Full Text] [Related]
19. Breast Cancer Neoantigens Can Induce CD8
Zhang X; Kim S; Hundal J; Herndon JM; Li S; Petti AA; Soysal SD; Li L; McLellan MD; Hoog J; Primeau T; Myers N; Vickery TL; Sturmoski M; Hagemann IS; Miller CA; Ellis MJ; Mardis ER; Hansen T; Fleming TP; Goedegebuure SP; Gillanders WE
Cancer Immunol Res; 2017 Jul; 5(7):516-523. PubMed ID: 28619968
[TBL] [Abstract][Full Text] [Related]
20. Efficient identification of mutated cancer antigens recognized by T cells associated with durable tumor regressions.
Lu YC; Yao X; Crystal JS; Li YF; El-Gamil M; Gross C; Davis L; Dudley ME; Yang JC; Samuels Y; Rosenberg SA; Robbins PF
Clin Cancer Res; 2014 Jul; 20(13):3401-10. PubMed ID: 24987109
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]